{"id":"NCT02163902","sponsor":"Kythera Biopharmaceuticals","briefTitle":"Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101","officialTitle":"A Multicenter, Double-blind, Nontreatment, Long-term Follow up Study of Subjects Who Completed ATX-101 (Deoxycholic Acid Injection) Clinical Trials ATX-101-11-22 or ATX-101-11-23 for the Reduction of Localized Subcutaneous Fat in the Submental Area","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2016-01","completion":"2016-08","firstPosted":"2014-06-16","resultsPosted":"2020-02-17","lastUpdate":"2020-02-17"},"enrollment":224,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"OTHER"},"conditions":["Submental Fat","Healthy"],"interventions":[{"type":"DRUG","name":"ATX-101","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ATX-101","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The investigation of the long-term safety and maintenance of efficacy of ATX-101 in reduction of submental fat.","primaryOutcome":{"measure":"Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits","timeFrame":"From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment","effectByArm":[{"arm":"ATX-101 (Deoxycholic Acid) Injection","deltaMin":86.4,"sd":null},{"arm":"Placebo","deltaMin":56.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":15,"countries":["United States","Canada"]},"refs":{"pmids":["33617632"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":113},"commonTop":[]}}